

A Randomised Double-Blind, Double Dummy Trial to Compare the Efficacy and Safety of Arimidex with Tamoxifen as First line Therapy for Advanced Breast Cancer in Post-Menopausal Women

Submission date 19/08/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 19/08/2002	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 28/11/2019	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
ZEN1033IL/27

Study information

Scientific Title

A Randomised Double-Blind, Double Dummy Trial to Compare the Efficacy and Safety of Arimidex with Tamoxifen as First line Therapy for Advanced Breast Cancer in Post-Menopausal Women

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised Double-Blind Double Dummy Trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Breast cancer

Interventions

1. Group A: Arimidex (anastrozole) 1 mg plus tamoxifen placebo daily
2. Group B: Tamoxifen 20 mg plus Arimidex placebo daily

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Arimidex with Tamoxifen

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/07/1998

Eligibility

Key inclusion criteria

1. Patients with locally advanced or metastatic breast cancer who are candidates to receive hormonal therapy as first line therapy for advanced disease (patients may have received adjuvant chemotherapy or hormonal therapy but patients who have received tamoxifen as adjuvant therapy must have an interval of at least 12 months since stopping tamoxifen and entry into this trial)
2. Post-menopausal defined as:
 - 2.1 Aged >50 years or who have not menstruated during the preceding 12 months or who have follicle-stimulating hormone (FSH) levels within the post-menopausal range
 - 2.2 Women aged <50 years who have FSH levels within the post-menopausal range
3. Hormone receptor (oestrogen receptor and or progesterone receptor) positive or unknown
4. Measurable or evaluable disease
5. No previous systemic therapy for advanced breast cancer
6. No drug-maintained menopausal status
7. No evidence of life threatening visceral disease
8. Life expectancy of >3 months
9. No treatment with a non-approved or experimental drug within the preceding 3 months before randomisation
10. No prior history of other malignancy other than breast cancer, except basal cell or squamous cell carcinoma of the skin or cancer of the cervix which has been satisfactorily controlled
11. No contraindications to protocol treatments

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1996

Date of final enrolment

01/07/1998

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
AstraZeneca Clinical Research Group (UK)

ROR
<https://ror.org/04r9x1a08>

Funder(s)

Funder type
Industry

Funder Name
AstraZeneca Pharmaceuticals (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration